Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07772960
PHASE1

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

Key Details

Gender

All

Age Range

18 Years - 68 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-10-01

Completion Date

2031-10-31

Last Updated

2026-08-19

Healthy Volunteers

No

Interventions

OTHER

Placebo

Placebo - administered one weekly for 20 weeks

DRUG

Semaglutide 1.0 mg

Semaglutide 1.0 mg low dose

DRUG

Semaglutide 2.0 mg

Semaglutide 2.0 mg high dose

Locations (1)

Yale Stress Center

New Haven, Connecticut, United States